NCT07132957View on ClinicalTrials.gov

A Study of AL8326 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 21, 2025

Primary Completion Date

May 17, 2025

Study Completion Date

May 17, 2025

Conditions
Small Cell Lung CancerSolid Tumors
Interventions
DRUG

14C-labeled AL8326

Oral, About 60mg (200μCi) of 14C-labeled AL8326

Trial Locations (1)

215006

The First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Advenchen Laboratories Nanjing Ltd.

INDUSTRY

NCT07132957 - A Study of AL8326 in Healthy Subjects | Biotech Hunter | Biotech Hunter